explore -WSS

explore

author：leisure time 2025-09-03 14:37:58 - browse：279

Susan Tousi is leaving Illumina to become CEO of cancer liquid-biopsy startup Delfi. Nasdaq

Delfi Diagnostics, a startup devising new ways to use routine blood draws to detect early signs of cancer, told STAT Thursday that it has appointed Susan Tousi, chief commercial officer for genomics giant Illumina, as its new CEO. She is the fourth senior executive to leave Illumina since June.

Tousi will start next week, just in time for the J.P. Morgan Healthcare Conference, while founding CEO Victor Velculescu will remain on the company’s board to help guide its research programs. Tousi’s selection is part of a bid by Delfi to expand its commercial efforts and build on the initial launch of its lung cancer screening test last fall, the latest example of growing interest in the vast and increasingly competitive liquid biopsy market.

Illumina’s own ambitions to enter this space recently came undone after a prolonged battle with U.S. and European regulators finally pushed the company to announce last month that it would divest Grail, which it had acquired for $8 billion two years earlier. Bas Verhoef, Illumina’s head of region for Europe, will serve as interim chief commercial officer.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical leaders decry Supreme Court decision on affirmative action
Next article： Akili changes sales model for its ADHD video game treatment

WSS

Amylyx and the next ALS drug test, plus a chat with CRISPR's CEO

Study gives hint on South Asians’ higher risk of cardiovascular disease

FDA weighs limits of animal data in assessing artificial wombs

FDA weighs limits of animal data in assessing artificial wombs

Study gives hint on South Asians’ higher risk of cardiovascular disease

Eli Lilly reports tirzepatide MASH success during Q4 earnings

focus

explore

leisure time

Continuity nursing helped my family in our darkest PICU moments

David Liu startup to focus on CRISPR delivery

New air purifier tech could be key to improving indoor air quality

Senate bill would ban some hospital facility fees

Psychedelics group wrestles with new pharma identity

Transgender sports debate: Physicians say bans are health issue

Cancer drug shortages should be causing more outrage

Too many hospitalized Covid

The cancer drug shortage isn’t new — and neither are the solutions

FDA panel to weigh safety of artificial wombs for preterm births

knowledge

Why the quest to eradicate polio has stumbled

Having children helps parents live longer, especially after age 80

Transgender sports debate: Physicians say bans are health issue

Midwives could help bridge maternal health disparities in the U.S.

Patients, doctors press FTC to beef up hospital merger scrutiny

Neurocrine congenital adrenal hyperplasia trial succeeds

explore

hotspot

leisure time

knowledge